International Clinical Trial: A multicenter, prospective, exploratory study evaluating an all-oral combination of Ivosidenib, Sonrotoclax, and Chidamide for the treatment of newly diagnosed IDH1-mutated acute myeloid leukemia

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131633) titled 'A multicenter, prospective, exploratory study evaluating an all-oral combination of Ivosidenib, Sonrotoclax, and Chidamide for the treatment of newly diagnosed IDH1-mutated acute myeloid leukemia' on Sept. 4.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Condition: Acute Myeloid Leukemia

Intervention: ISC Plan Queue Group 1:Ivosidenib 500 mg orally once daily (qd), chidamide 10 mg orally once daily on days 1-28, and sotoclax orally at 40 mg on day 1, 80 mg on day 2, 160 mg on day 3, and 320 mg on days 4-10...